Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
Key Highlights
- ➤Protara (TARA) completes enrollment in 24-patient Phase 2b dose-confirmation cohort
- ➤Interim Phase 2b results remain expected in 4Q 2026
- ➤Phase 3 planned as randomized, double-blind trial enrolling approximately 100 patients
- ➤IV Choline Chloride targets choline deficiency in parenteral-support-dependent patients
Expert Statements
Jesse Shefferman, Chief Executive Officer at Protara Therapeutics
“We are excited about our progress in the registrational THRIVE-3 trial, which brings us one step closer to a solution for patients on parenteral support.”
Jesse Shefferman, Chief Executive Officer at Protara Therapeutics
“Choline plays a critical role in liver function, yet there are currently no approved PS formulations containing choline, leaving approximately 80 percent of the roughly 30,000 PS-dependent adult patients in the U.S. with choline deficiency.”
Jesse Shefferman, Chief Executive Officer at Protara Therapeutics
“The majority of these patients suffer from some degree of liver damage.”
Jesse Shefferman, Chief Executive Officer at Protara Therapeutics
“We believe IV Choline Chloride has the potential to become the first FDA-approved IV Choline formulation for PS patients.”
Jesse Shefferman, Chief Executive Officer at Protara Therapeutics
“We look forward to reporting interim results from the Phase 2b dosing cohort of THRIVE-3 in the fourth quarter of this year.”
Company remains on track to report interim results from Phase 2b cohort in 4Q 2026
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has completed enrollment of the Phase 2b, open-label dose confirmation phase of the THRIVE-3 clinical trial evaluating IV Choline Chloride in patients with intestinal failure who are dependent on parenteral support (PS). The dose confirmation phase of the trial includes 24 patients.
Get started
Create a free account to read the full story.